Company Profile

QRxPharma Ltd. (ASX:  QRX) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders.  On May 25, 2007, QRxPharma completed an underwritten initial public offering under the symbol “QRX” on the Australian Securities Exchange (ASX). 

Based on a business strategy to expand the clinical utility and commercial value of marketed and/or existing compounds, the Company’s product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk of failure, abbreviated development paths, and improved patient outcomes.  QRxPharma intends to directly commercialise its products in the US and seek strategic partnerships abroad.  QRxPharma’s lead compound, MoxDuo™ IR (Q8003 IR), began Phase 3 clinical trials in November 2007.  The Company’s preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics.

Click here to download our corporate one-sheet. [PDF]

Click here to watch welcome message from John Holaday, Managing Director and CEO.